Nature communications · 2024
Structuring lipid nanoparticles, DNA, and protein corona into stealth bionanoarchitectures for in vivo gene delivery.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Renzi Serena, Digiacomo Luca, Pozzi Daniela, Quagliarini Erica, Vulpis Elisabetta, Giuli Maria Valeria, Mancusi Angelica, Natiello Bianca, Pignataro Maria Gemma, Canettieri Gianluca, Di Magno Laura, Pesce Luca, De Lorenzi Valentina, Ghignoli Samuele, Loconte Luisa, Montone Carmela Maria, Laura Capriotti Anna, Laganà Aldo, Nicoletti Carmine, Amenitsch Heinz, Rossi Marco, Mura Francesco, Parisi Giacomo, Cardarelli Francesco, Zingoni Alessandra, Checquolo Saula, Caracciolo Giulio
Аннотация
Lipid nanoparticles (LNPs) play a crucial role in addressing genetic disorders, and cancer, and combating pandemics such as COVID-19 and its variants. Yet, the ability of LNPs to effectively encapsulate large-size DNA molecules remains elusive. This is a significant limitation, as the successful delivery of large-size DNA holds immense potential for gene therapy. To address this gap, the present study focuses on the design of PEGylated LNPs, incorporating large-sized DNA, departing from traditional RNA and ionizable lipids. The resultant LNPs demonstrate a unique particle morphology. These particles were further engineered with a DNA coating and plasma proteins. This multicomponent bionanoconstruct exhibits enhanced transfection efficiency and safety in controlled laboratory settings and improved immune system evasion in in vivo tests. These findings provide valuable insights for the design and development of bionanoarchitectures for large-size DNA delivery, opening new avenues for transformative gene therapies.